Answers are grounded in this paper and cite their sources.
A reduced graphene oxide/cuprous oxide (RGO/Cu2O) nanocomposite has been successfully synthesized applying a simple in situ reduction method using an aqueous solution of lactulose which is used simultaneously as a reducing and stabilizing agent. Lactulose, a disaccharide, has the ability to reduce both GO and CuSO4 in situ under alkaline conditions. The GO and RGO/Cu2O nanocomposites are characterized using transmission electron microscopy, energy dispersive X-ray spectroscopy, field emission scanning electron spectroscopy, X-ray diffraction, Fourier-transform infrared spectroscopy and UV-vis absorption spectroscopy. The surface charge as well as stability is established by analyzing the zeta potential value. The results confirm the synthesis of the RGO/Cu2O nanocomposite and the existence of interactions between Cu2O and RGO. It is also observed that Cu2O nanoparticles with an average size of 5 nm are uniformly dispersed throughout the RGO sheets. The catalytic activity of the RGO/Cu2O nanocomposite is excellent for the ‘click’ reaction and remains the same for six cycles.
No takes yet. Share an insight, caveat, or question.
Roy et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: